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Background: Deep vein thrombosis (DVT) is the formation of blood clots (thrombi) in the 
deep veins. It commonly affects the deep leg veins (such as the calf veins, femoral vein, or 
popliteal vein) or the deep veins of the pelvis. It is a potentially dangerous condition that can 
lead to preventable morbidity and mortality.
Aim: To present an update on the causes and management of DVT.
Methods: A review of publications obtained from Medline search, medical libraries, and 
Google.
Results: DVT affects 0.1% of persons per year. It is predominantly a disease of the elderly and 
has a slight male preponderance. The approach to making a diagnosis currently involves an algo-
rithm combining pretest probability, D-dimer testing, and compression   ultrasonography. This will 
guide further investigations if necessary. Prophylaxis is both mechanical and   pharmacological. 
The goals of treatment are to prevent extension of thrombi, pulmonary embolism, recurrence 
of thrombi, and the development of complications such as pulmonary hypertension and post-
thrombotic syndrome.
Conclusion: DVT is a potentially dangerous condition with a myriad of risk factors. Prophylaxis 
is very important and can be mechanical and pharmacological. The mainstay of treatment is 
anticoagulant therapy. Low-molecular-weight heparin, unfractionated heparin, and vitamin K 
antagonists have been the treatment of choice. Currently anticoagulants specifically targeting 
components of the common pathway have been recommended for prophylaxis. These include 
fondaparinux, a selective indirect factor Xa inhibitor and the new oral selective direct thrombin 
inhibitors (dabigatran) and selective factor Xa inhibitors (rivaroxaban and apixaban). Others 
are currently undergoing trials. Thrombolytics and vena caval filters are very rarely indicated 
in special circumstances.
Keywords: deep vein thrombosis, pulmonary embolism, venous thromboembolism,   prophylaxis, 
treatment
Introduction
The term thrombosis refers to the formation, from constituents of blood, of an abnormal 
mass within the vascular system of a living animal. When this process occurs within 
the deep veins, it is referred to as deep vein thrombosis (DVT).
An accurate diagnosis of DVT is extremely important to prevent potentially fatal 
acute complication of pulmonary embolism (PE) and long-term complications of 
postphlebitis syndrome and pulmonary hypertension. It is also important to avoid 
unjustified therapy with anticoagulants with associated high risk of bleeding in patients 
misdiagnosed with the condition.1Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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Clinical features are nonspecific; hence new strategies 
for diagnosing this condition have evolved.
We aim to critically review the current state of knowledge 
on this subject, with a view to updating clinicians on the 
prophylaxis and treatment of DVT.
Methods
A literature review of DVT was done from 1970 to date using 
a manual library search, journal publications on the subject, 
and Medline. Full texts of the materials, including those of 
relevant references were collected and studied. Information 
relating to the epidemiology, pathology, clinical presentation, 
investigations, prophylaxis, treatment, and complications was 
extracted from the materials.
Results
epidemiology
DVT is a major and a common preventable cause of death 
worldwide. It affects approximately 0.1% of persons per 
year. The overall average age- and sex-adjusted annual 
incidence of venous thromboembolism (VTE) is 117 per 
100,000 (DVT, 48 per 100,000; PE, 69 per 100,000), with 
higher age-adjusted rates among males than females (130 
vs 110 per 100,000, respectively).2 Both sexes are equally 
afflicted by a first VTE, men having a higher risk of recurrent 
thrombosis.3,4 DVT is predominantly a disease of the elderly 
with an incidence that rises markedly with age.2
A study by Keenan and White revealed that African-
American patients are the highest risk group for first-time 
VTE. Hispanic patients’ risk is about half that of Caucasians. 
The risk of recurrence in Caucasians is lower than that of 
African-Americans and Hispanics.5
The incidence of VTE is low in children. Annual inci-
dences of 0.07 to 0.14 per 10,000 children and 5.3 per 
10,000 hospital admissions have been reported in Cauca-
sian studies.6,7 This low incidence may be due to decreased 
capacity to generate thrombin, increased capacity of 
  alpha-2-macroglobulin to inhibit thrombin, and enhanced 
antithrombin potential of vessel walls. The highest incidence 
in childhood is during the neonatal period, followed by 
another peak in adolescence.8 The incidence rate is compara-
tively higher in adolescent females because of pregnancy and 
use of oral contraceptive agents.9
Pregnant women have a much higher risk of VTE than 
nonpregnant women of similar age and the risk has been 
shown to be higher after cesarian section than after vaginal 
delivery.10 In a study conducted in an African population, the 
documented rate was 48 DVT per 100,000 births per year.11 
The incidence appears to be highest in the postpartum 
period.11,12
The approximate risk for DVT following general surgery 
procedures is 15% to 40%. It nearly doubles after hip or 
knee replacement surgery or hip fracture surgery (40% to 
60%).13 Geerts et al revealed that without prophylaxis, fatal 
PE occurs in 0.2% to 0.9% of patients undergoing elective 
general surgery, 0.1% to 2% of those undergoing elective 
hip replacement and up to 2.5% to 7.5% of those   undergoing 
surgery for hip fracture.14 Though regarded mainly as a surgi-
cal complication, most symptomatic VTE events and fatal 
PE occur in medical patients.15
Pathogenesis/classification
Thrombus formation preferentially starts in the valve pockets 
of the veins of the calf and extends proximally. This is espe-
cially true for those that occur following surgery.16 Though 
most thrombi begin intraoperatively, some start a few days, 
weeks, or months after surgery. Lending its support to the 
origin of thrombus in valve pockets is a recent hypothesis 
of an increased expression of endothelial protein C receptor 
(EPCR) and thrombomodulin (TM) and a decreased expres-
sion of Von Willebrand factor (vWF) noted in valve sinus 
endothelium compared with vein luminal endothelium. This 
means an upregulation of anticoagulants (EPCR, TM) and 
a downregulation of procoagulant (vWF) properties of the 
valvular sinus endothelium.17
Thrombus is composed predominantly of fibrin and red 
cells (red or static thrombus). Venous thrombus must be 
differentiated from postmortem clot at autopsy. Postmortem 
clots are gelatinous and have a dark red dependent   portion 
(formed by red cells that have settled by gravity and a   yellow 
chicken fat supernatant resembling melted and clotted 
chicken fat). They are usually not attached to the underly-
ing wall. This is in contrast to the venous thrombi which are 
firmer. They almost always have a point of attachment to 
the wall and transection reveals vague strands of pale gray 
fibrin.18
DVT in the lower limb can be classified as a) proximal, 
when the popliteal vein or thigh veins are involved or b) 
distal, when the calf veins are involved. Clinically, proximal 
vein thrombosis is of greater importance and is associated 
with serious chronic diseases such as active cancer, conges-
tive cardiac failure, respiratory insufficiency, or age above 
75 years, whereas distal thrombosis is more often associated 
with risk factors such as recent surgery and immobilization. 
Fatal PE is far more likely to result from proximal DVT.19 
Post-thrombotic syndrome, a chronic, potentially disabling Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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condition characterized by leg swelling, pain, venous ectasia, 
and skin induration, is established by 1 year after DVT in 
17% to 50% of cases.20
Uncommon presentations of VTE are forms of acute 
massive venous thrombosis with obstruction of venous 
drainage to the extremity. These include phlegmasia alba 
dolens, phlegmasia cerulea dolens, and venous gangrene. 
In phlegmasia alba dolens, the thrombosis involves only 
the major deep venous channels of the extremity, sparing 
collateral veins. However, in phlegmasia cerulea dolens, the 
thrombosis extends to the collateral vein, resulting in massive 
fluid sequestration and more significant edema.
Clinical features
History and clinical examination are not reliable ways of 
diagnosing DVT.21 Lower extremity DVT can be symptomatic 
or asymptomatic. Patients with lower extremity DVT often 
do not present with erythema, pain, warmth, swelling, or 
tenderness. Symptomatic patients with proximal DVT may 
present with lower extremity pain, calf tenderness, and lower 
extremity swelling.22,23 Homans’ sign may be demonstrable in 
DVT. Most of these features lack specificity; hence clinical 
evaluation usually implies the need for further evaluation. 
The left leg is the commonest site for venous thrombosis in 
pregnancy11 and in acute massive venous thrombosis. This 
may be due to compression of the left iliac vein by the right 
iliac artery (May–Thurner syndrome).24
Phlegmasia alba dolens is characterized by edema, pain, 
and blanching without cyanosis while phlegmasia cerulea 
dolens is characterized by these features in addition to 
cyanosis, which characteristically progresses from distal to 
proximal areas and bleb/bulla formation.
Risk factors
Rudolph Virchow described three conditions that predispose 
to thrombus, the so-called Virchow’s triad. This triad includes 
endothelial injury, stasis or turbulence of blood flow, and 
blood hypercoagulability.
Stasis and endothelial injury are important in DVT 
following trauma or surgery while hypercoagulability is 
responsible for most cases of spontaneous DVT. At least 
96% of patients treated for VTE have been shown to have 
at least one risk factor.25
Risk can be classified as acquired or genetic. When 
genetic defects are combined with one or more acquired risk 
factors, or in combined genetic defects or combination of two 
acquired defects, it results in a risk of VTE that exceeds the 
separate effects of a single factor.26
In adults, the clinical conditions that predispose to VTE 
are increasing age, cancer and its treatment, prolonged 
immobility, stroke or paralysis, previous VTE, congestive 
heart failure, acute infection, pregnancy or puerperium, 
dehydration, hormonal treatment, varicose veins, long air 
travel, acute inflammatory bowel disease, rheumatological 
disease, and nephrotic syndrome. Other acquired factors 
that have recently been associated with increased risk of 
VTE disorders include persistent elevation of D-dimer and 
atherosclerotic disease.27
Oral contraceptive pills, especially those that contain 
third-generation progestins increase the risk of VTE.28 Risk 
of DVT associated with long-duration air travel is called 
economy class syndrome.29 It is 3% to 12% in a long-haul 
flight with stasis, hypoxia, and dehydration being pathophysi-
ological changes that increase the risk.30 van Aken et al dem-
onstrated that subjects with elevated levels of interleukin-8 
have increased risk of venous thrombosis, supporting an 
important role of inflammation in etiopathogenesis of venous 
thrombosis.31
Clayton et al have described a strong association between 
recent respiratory infection and VTE. They demonstrated 
an increased risk of DVT in the month following infection 
and PE in 3 months following infection, both persisting up 
to a year.32
In the pediatric age group, the most important triggering 
risk factors for development of thromboembolism are the 
presence of central venous lines, cancer, and chemotherapy. 
Severe infection, sickle cell disease, trauma, and antiphos-
pholipid syndromes are clinical conditions associated with 
hypercoagulability states.33
Genetic risk factors can be divided into strong, moderate, 
and weak factors.34 Strong factors are deficiencies of anti-
thrombin, protein C and protein S. Moderately strong factors 
include factor V Leiden, prothrombin 20210A, non-O blood 
group, and fibrinogen 10034T. Weak genetic risk factors 
include fibrinogen, factor XIII and factor XI variants.
Clinical prediction rules
A commonly accepted evidence-based approach to diagno-
sis of VTE is the use of a clinical model that standardizes 
the clinical assessment (combining risk factors, signs and 
symptoms) and subsequently stratifies patients suspected 
of DVT.
Though this model has been used for both primary care 
patients and secondary settings, there is no doubt that it does 
not guarantee accurate estimation of risk in primary care 
patients in whom DVT is suspected.35Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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The most commonly recommended model is that 
developed by Wells and colleagues. Based on clinical pre-
sentation and risk factors, an initial model was developed 
to group patients into low-, moderate-, and high-probability 
groups. The high-probability group has an 85% risk of 
DVT, the moderate-probability group a 33% risk, and the 
  low-probability group a 5% risk.36 However, in a later study, 
Wells and colleagues further streamlined the diagnostic pro-
cess by stratifying patients into two risk categories: “DVT 
unlikely” if the clinical score is #1 and “DVT likely” if the 
clinical score is .1 (Table 1).37
D-dimer assay
D-dimer is a degradation product of cross-linked fibrin that 
is formed immediately after thrombin-generated fibrin clots 
are degraded by plasmin. It reflects a global activation of 
blood coagulation and fibrinolysis.38 It is the best recognized 
biomarker for the initial assessment of suspected VTE. The 
combination of clinical risk stratification and a D-dimer test 
can exclude VTE in more than 25% of patients presenting 
with symptoms suggestive of VTE without the need for 
additional investigations.39 Even in patients with clinically 
suspected recurrent DVT, this combination (clinical evalu-
ation and D-dimer) has proved to be useful for excluding 
DVT, especially in patients included in the lower clinical 
pretest probability group.40
Levels of D-dimer can be popularly measured using three 
types of assay:
•	 Enzyme linked immunosorbent assay (ELISA).
•	 Latex agglutination assay.
•	 Red blood cell whole blood agglutination assay 
(simpliRED).
These assays differ in sensitivity, specificity, likelihood 
ratio, and variability among patients with suspected VTE. 
ELISAs dominate the comparative ranking among D-dimer 
assays for sensitivity and negative likelihood ratio.
D-dimer assays are highly sensitive (values up to 95%), 
but have poor specificity to prove VTE. The negative predic-
tive value for patients with a negative D-dimer blood test is 
nearly 100%. Hence a negative value of D-dimer may safely 
rule out both DVT and PE. False positive D-dimer results 
have been noted in inflammation,41 pregnancy,42 malignancy,43 
and the elderly.44 Clinical usefulness of the measurement of 
D-dimer has been shown to decrease with age.45 The use 
of age-dependent cut-off values of D-dimer assays is still a 
matter of controversy. Several studies have shown that the 
levels of D-dimer assays increase with gestational age and 
in complicated pregnancies as observed in preterm labor, 
abruptio placenta, and gestational hypertension.46–48 Elevated 
D-dimer was found to be predictive of poor outcome (per-
sistent thrombosis, recurrence or post-thrombotic syndrome) 
in children with an acute thrombotic event.49 False negative 
D-dimer results have been noted after heparin use; hence it 
has been recommended that D-dimer assay should be done 
prior to administering heparin to a patient.43 Other causes of 
false negative D-dimer results are late presentation (symp-
toms longer than 2 weeks) and small below-knee DVT.
venous ultrasonography
Venous ultrasonography is the investigation of choice in 
patients stratified as DVT likely.50 It is noninvasive, safe, 
available, and relatively inexpensive. There are three types 
of venous ultrasonography: compression ultrasound (B-mode 
imaging only), duplex ultrasound (B-mode imaging and 
  Doppler waveform analysis), and color Doppler imaging 
alone. In duplex ultrasonography, blood flow in normal vein 
is spontaneous, phasic with respiration, and can be augmented 
by manual pressure. In color flow sonography, pulsed Doppler 
signal is used to produce images.51 Compression ultrasound is 
typically performed on the proximal deep veins, specifically 
the common femoral, femoral, and popliteal veins, whereas 
a combination of duplex ultrasound and color duplex is more 
often used to investigate the calf and iliac veins.52
The major ultrasonographic criterion for detecting venous 
thrombosis is failure to compress the vein lumen under gentle 
probe pressure. Other criteria for ultrasonographic diagnosis 
of venous thrombosis include loss of phasic pattern in which 
flow is defined as continuous, response to valsava or augmen-
tation (Duplex ultrasound), and complete absence of spectral 
or color Doppler signals from the vein lumen.53
The other advantages of venous ultrasound are its ability to 
diagnose other pathologies (Baker’s cysts, superficial or intra-
muscular hematomas, lymphadenopathy, femoral aneurysm, 
superficial thrombophlebitis, and abscess), and the fact that 
there is no risk of exposure to irradiation, while its major limita-
tion is its reduced ability to diagnose distal thrombus.22 Venous 
compressibility may be limited by a patient’s characteristics 
such as obesity, edema, and tenderness as well as by casts or 
immobilization devices that limit access to the extremity. Com-
pression B-mode ultrasonography with or without color Duplex 
imaging has a sensitivity of 95% and a specificity of 96% for 
diagnosing symptomatic, proximal DVT.54 For DVT in the calf 
vein, the sensitivity of venous ultrasound is only 73%.55
Repeat or serial venous ultrasound examination is 
indicated for initial negative examination in symptomatic 
patients who are highly suspicious for DVT and in whom Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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an alternative form of imaging is contraindicated or not 
  available. Serial testing has been found unnecessary for those 
in whom DVT is unlikely by Wells score and has a negative 
D-dimer test.
Contrast venography
Venography is the definitive diagnostic test for DVT, but it 
is rarely done because the noninvasive tests (D-dimer and 
venous ultrasound) are more appropriate and accurate to 
perform in acute DVT episodes. It involves cannulation of 
a pedal vein with injection of a contrast medium, usually 
noniodinated, eg, Omnipaque. A large volume of Omnipaque 
diluted with normal saline results in better deep venous filling 
and improved image quality.56
The most reliable cardinal sign for the diagnosis of 
phlebothrombosis using venogram is a constant intraluminal 
filling defect evident in two or more views.56 Another reliable 
criterion is an abrupt cutoff of a deep vein, a sign difficult to 
interpret in patients with previous DVT.57 It is highly sensitive 
especially in identifying the location, extent and attachment 
of a clot and also highly specific.
Being invasive and painful remains its major setback. The 
patient is exposed to irradiation and there is also an additional 
risk of allergic reaction and renal dysfunction. Occasionally 
a new DVT may be induced by venography,58 probably due 
to venous wall irritation and endothelial damage. The use of 
nonionic contrast medium has reduced considerably risks of 
anaphylactic reaction and thrombogenecity or may have even 
eliminated them.59,60
impedance plethysmography
The technique is based on measurement of the rate of change 
in impedance between two electrodes on the calf when a 
venous occlusion cuff is deflated. Free outflow of venous 
blood produces a rapid change in impedance while delay in 
outflow, in the presence of a DVT, leads to a more gradual 
change.61 It is portable, safe, and noninvasive but its main 
drawback remains an apparent insensitivity to calf thrombi 
and small, nonobstructing proximal vein thrombi.
Magnetic resonance imaging (MRi)
This investigative modality has high sensitivity in detect-
ing calf and pelvic DVTs,62 and upper extremity venous 
thromboses.63 It is also relevant in ruling out differential 
diagnoses in patients suspected of DVT. MRI is the diag-
nostic test of choice for suspected iliac vein or inferior vena 
caval thrombosis when computed tomography venography 
is contraindicated or technically inadequate. There is no 
risk of ionizing radiation but it is costly, scarce, and reader 
expertise is required.
Algorithm for the diagnosis of DvT 
The first step is the pretest probability assessment using an 
established model such as the Wells score (Figure 1). If score 
is #1 (DVT unlikely), D-dimer assay is done. If assay is 
negative, DVT is excluded and the patient can be discharged 
without further investigations. If assay is positive, a venous 
ultrasound is indicated. Negative venous ultrasound scan 
excludes the diagnosis of DVT. Diagnosis of DVT is made 
if venous ultrasonography is positive.
If the DVT is likely (probability score $2), venous 
ultrasonography is indicated. DVT is diagnosed and treated 
if venous ultrasound is positive. If negative, D-dimer assay 
should be done. Negative D-dimer excludes the diagnosis 
of DVT while a positive result is an indication for follow-up 
studies; repeat ultrasound in 6 to 8 days or do venography. 
This algorithm is not used in pregnancy because D-dimer is 
falsely elevated.
Prophylaxis
Mechanical
Mechanical methods of prophylaxis against DVT include 
intermittent pneumatic compression (IPC) device, graduated 
compression stocking (GCS), and the venous foot pump. 
Intermittent pneumatic compression enhances blood flow 
in the deep veins of the leg, preventing venous stasis and 
hence preventing venous thrombosis.64 Agu et al have shown 
that these mechanical methods reduce postoperative venous 
thrombosis.65 A Cochrane review showed a reduction of 
Table 1 Pretest probability assessment (wells score)
Points
Active cancer (treatment ongoing or within previous 
6 months or palliative)
1
Paralysis, paresis, or recent plaster immobilization of the 
lower extremities
1
Recently bedridden for 3 days or major surgery within  
12 weeks requiring general or regional anesthesia
1
Localized tenderness along the distribution of the deep 
veins
1
entire leg swollen 1
Calf swelling 3 cm . asymptomatic side (measured 10 cm 
below tibial tuberosity)
1
Pitting edema limited to the symptomatic leg 1
Collateral superficial veins (nonvaricose) 1
Previous DvT 1
Alternative diagnosis as likely as or more likely than DvT −2
Notes: DvT unlikely: #1; DvT likely: $2Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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VTE by about 50% with the use of graduated compression 
stockings.66 Intermittent pneumatic compression, in addition 
to preventing venous thrombosis, has been shown to reduce 
plasminogen activator inhibitor-1, thereby increasing endog-
enous fibrinolytic activity.67
Compared with compression alone, combined prophy-
lactic modalities decrease significantly the incidence of 
VTE. Compared with pharmacological prophylaxis alone, 
combined modalities reduce significantly the incidence of 
DVT, but the effect on PE is unknown. This is recommended 
especially for high-risk patients.68
A mechanical method of DVT prophylaxis is indicated 
in patients at high risk of bleeding with anticoagula-
tion prophylaxis. These includes patients with active or 
recent gastrointestinal bleeding, patients with hemor-
rhagic stroke, and those with hemostatic defects such as 
severe   thrombocytopenia.69 It is contraindicated in patients 
with evidence of leg ischemia due to peripheral vascu-
lar   disease. There is a theoretical risk of fibrinolysis and 
clot   dislodgement.70 Leg wrappings and stockings with no 
  pressure gradient are ineffective in the prevention of DVT.71 
Hilleren-Listerud demonstrated that knee-length GCS and 
IPC devices are as effective as thigh-length GCS and IPC 
devices. They are also more comfortable, cheaper and more 
user-friendly for the patient.72
Chin et al compared the efficacy and safety of differ-
ent modes of thromboembolic prophylaxis (IPC, GCS, and 
enoxaparin) for elective total knee arthroplasty (TKA) in 
Asian patient and recommended IPC as the preferred method 
of thromboprophylaxis for TKA.73 However no meaningful 
difference in performance between GCS and IPC was dem-
onstrated by Morris and Woodcock.74
Daily use of elastic compression stockings after proxi-
mal DVT reduced the incidence of postphlebitis syndrome 
by 50%.20
Other mechanical means in both medical and surgical 
patients include ambulation and exercises involving foot exten-
sion. They improve venous flow and should be encouraged.
Pharmacological
Unfractionated heparin (UFH), low-molecular-weight 
heparins (LMWH), fondaparinux, and the new oral direct 
selective thrombin inhibitors and factor Xa inhibitors are 
Table 2   Advantages  of  low-molecular-weight  heparin  over 
unfractionated heparin
• Greater bioavailability
• Predictability and dose-dependent plasma level
• Less risk of bleeding
• Lower incidence of heparin-induced thrombocytopenia
• Lower risk of heparin-induced osteoporosis
• No need for laboratory monitoring
• Can be safely administered in outpatient
•   Duration of anticoagulant effect is longer, permitting once- or  
twice-daily administration
Clinical probability 
Clinical features and risk factors (DVT) 
DVT unlikely
(probability score ≤ 1)
D-dimer assay
Negative
DVT excluded
DVT Follow up studies
(repeat venous USS in
a week or venography)
DVT likely
(probability score ≥ 2)
Venous USS
Positive Negative Positive
Negative Positive Negative Positive
D-dimer assay Diagnose/treat
DVT
Venous USS
DVD diagnose/treat DVT excluded DVT excluded
Figure 1 Algorithm for diagnosing DvT using clinical assessment, D-dimer testing, and venous ultrasonography.
Abbreviation: USS, ultrasound.Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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effective pharmacological agents for prophylaxis of DVT. 
Studies have shown that the incidence of all DVTs, proximal 
DVT, and all PE including fatal PE has been reduced by 
low-dose UFH.75,76
LMWH has additional advantages over unfractionated 
  heparin (Table 2). It can be given once or twice daily without 
laboratory   monitoring. Other advantages are predictability, 
dose-dependent plasma levels, a long half-life, less bleeding 
for a given antithrombotic effect, and a lower incidence of 
heparin-induced thrombocytopenia than with UFH.77
The risk of heparin-induced osteoporosis is lower with 
LMWH than with UFH as it does not increase osteoclast 
number and activity.78 It has a far greater effect on inhibi-
tion of factor Xa and a lesser effect on antithrombin III by 
inhibiting thrombin to a lesser extent than UFH.79 Current 
contraindications to the early initiation of LMWH throm-
boprophylaxis include the presence of intracranial bleeding, 
ongoing and uncontrolled bleeding elsewhere, and incom-
plete spinal cord injury associated with suspected or proven 
spinal hematoma.
Fondaparinux, a synthetic pentasaccharide, has been 
approved for prophylaxis of DVT. It is an indirect selective 
inhibitor of factor Xa which binds to antithrombin with high 
affinity in a reversible manner. Heparin-induced thrombocy-
topenia has not been reported with fondaparinux as it does 
not interact with platelet function and aggregation, and has 
a predictable response.80 Monitoring of prothrombin time 
or partial thromboplastin time is also not required. In sum-
mary, it has an equal or better effectiveness than currently 
available agents, a low bleeding risk, no need for laboratory 
monitoring, and once daily administration.
Dabigatran is a new oral univalent direct thrombin 
inhibitor. Dabigatran etexilate is the prodrug of dabigatran. 
It is rapidly absorbed from the gastrointestinal tract with a 
bioavailability of 5% to 6%. It has a half-life of 8 hours after 
single-dose administration and up to 17 hours after multiple 
doses with plasma levels that peak at 2 hours.81 The drug 
is excreted largely unchanged via the kidneys. It has a low 
bioavailability (6%), produces a predictable anticoagulant 
effect, and requires no coagulation monitoring.81 Dabigatran 
has been approved in Canada and Europe for VTE prevention 
after orthopedic surgery.
The RE-COVER trial compared dabigatran etexilate with 
warfarin for 6 months in patients with acute VTE; dabigatran 
was as effective as warfarin in preventing recurrent VTE, 
with comparable major bleeding and significantly lower total 
bleeding rates.82,83 Another study (The RE-NOVATE II trial) 
compared the efficacy and safety of oral dabigatran with 
subcutaneous enoxaparin for extended thromboprophylaxis 
in patients undergoing total hip arthroplasty.82 Extended 
prophylaxis with oral dabigatran 220 mg once daily was as 
effective as subcutaneous enoxaparin 40 mg once daily in 
reducing the risk of VTE after total hip arthroplasty, and 
superior to enoxaparin for reducing the risk of major VTE. 
The risk of bleeding and safety profiles were similar.84
Rivaroxaban is a potent and selective oral factor Xa 
inhibitor. It has a rapid onset of action, a high bioavailability 
(80%), and a half-life of 4 to 12 hours.81 EINSTIEN-DVT 
trial has shown that oral rivaroxaban is as effective in prevent-
ing recurrence of symptomatic VTE as the current standard 
therapy of injectable LMWH, enoxaparin, or fondaparinux, 
and an oral vitamin K antagonist in well-managed patients.85 
The results of RECORD phase III trials have also shown 
that rivaroxaban 10 mg once daily is superior to the LMWH 
enoxaparin, when used for prophylaxis of VTE in orthopedic 
surgeries.86 The drug also has the major advantages of once 
daily oral dosing and no required laboratory monitoring. 
Other drugs in this group such as apixaban and edoxaban 
are currently undergoing clinical trials.
Oral anticoagulation with vitamin K antagonists such as 
warfarin can be commenced preoperatively, at the time of sur-
gery, or postoperatively for the prevention of VTE.87   Warfarin 
is contraindicated in antepartum thromboprophylaxis because 
it crosses the placenta and can result in unwanted teratoge-
nicity and bleeding in the fetus.88 However the drug is safe 
during lactation as it does not accumulate in the breast milk 
to a substantial extent.89 Unlike warfarin, heparin is safe and 
it is recommended both in pregnancy and lactation.90
The use of aspirin alone is not recommended for throm-
boprophylaxis against VTE for any patient group. Some 
studies on the use of aspirin as prophylactic agent for DVT 
have shown some degree of protection against VTE in hos-
pitalized patients,91,92 while other studies have either shown 
no benefit,93,94 or have proven to be less effective to other 
thromboprophylactic agents.95,96
The duration of thromboprophylaxis depends on the level 
of risk of VTE. For patients undergoing total hip replacement 
or hip fracture surgery, prolonged thromboprophylaxis beyond 
10 days and up to 35 days is recommended especially for patients 
who are considered to be at high risk for VTE, while in patients 
admitted with acute medical illness thromboprophylaxis should 
be continued until discharge for the majority of the patients.87
Treatment
The goal of therapy for DVT is to prevent the extension 
of thrombus, acute PE, recurrence of thrombosis, and the Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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development of late complications such as pulmonary 
hypertension and post-thrombotic syndromes. The initial 
treatment usually involves achieving a therapeutic dose of 
UFH or LMWH, or with fondaparinux.
Studies have shown that the efficacy of treatment with 
heparin largely depends on the ability to achieve a critical 
therapeutic ratio within the first 24 hours of treatment,97,98 
ie, achieving an activated partial thromboplastin time (aPTT) 
that is 1.5 times the mean of control value or the upper limit 
of normal aPTT range (aPTT ratio) of 1.5 to 2.5. This level 
corresponds to a heparin blood level of 0.3 to 0.7 U/mL by 
amidolytic antifactor Xa assay.99
Because of the advantages of LMWH, it is recommended 
over unfractionated UFH for treatment of acute DVT. UFH 
is, however, preferred in patients with severe renal failure 
as LMWH is mainly excreted via the kidneys. Heparin is 
initially given with warfarin and stopped after a minimum 
of 4 to 5 days, at which time the international normalized 
ratio (INR) should be within 2.0 to 3.0 (therapeutic range). 
This overlap with warfarin is essential because factors II, IX, 
X will not be affected until after 5 days, hence the intrinsic 
clotting pathway is intact. The initial prolongation of INR 
is mainly due to the effect of depression of factor VII which 
has a half-life of 5 to 7 hours.
Warfarin remains the drug of choice for long-term 
therapy to prevent clot formation once acute anticoagula-
tion is achieved. LMWH is, however, preferred after long-
term therapy of DVT in pregnancy as warfarin therapy is 
contraindicated,100 and in patients with cancer. Long-term 
anticoagulant therapy with LMWH is more effective than 
warfarin at preventing recurrent venous thrombosis in 
cancer patients without a statistically significant bleeding 
risk.101
The duration of anticoagulation depends on whether the 
patient has a first episode of DVT, ongoing risk factors for 
VTE disease, and known thrombophlebitis.102 In patients 
with first proximal DVT occurring in the context of a 
transient risk factor such as surgery or trauma, the risk of 
recurrence is very low and a limited duration of treatment 
(3 months) is adequate.103,104 Long-term anticoagulation 
therapy should be considered for recurrent thromboses, 
patients with ongoing risk such as active cancer and a first 
unprovoked proximal DVT or PE where no risk factors for 
bleeding are present, and where anticoagulation control is 
good. This may be particularly the case if D-dimer is raised 
after discontinuing anticoagulation, in males, in those with 
post-thrombotic syndrome, and in those with antiphospho-
lipid antibodies.43,105
Thrombolytic therapy
This is rarely indicated. The risk of major bleeding, including 
intracranial hemorrhage, should be weighed against the 
benefits of a complete and rapid lysis of thrombi. It is indi-
cated in massive DVT which leads to phlegmasia cerulean 
dolens and threatened limb loss. The available thrombolytic 
agents include tissue plasminogen activator, streptokinase, 
and urokinase.
Endovascular thrombolytic methods have evolved consid-
erably in recent years. Catheter-directed thrombolysis (CDT) 
can be used to treat DVTs as an adjunct to medical therapy.106 
Current evidence suggests that CDT can reduce clot burden 
and DVT recurrence and consequently prevent the formation of 
post-thrombotic syndrome compared with systemic anticoagu-
lation.106 Pharmacomechanical CDT is now routinely used in 
some centers for the treatment of acute iliofemoral DVT.107
Appropriate indications may include younger individuals 
with acute proximal thromboses, a long life expectancy, and 
relatively few comorbidities. Limb-threatening thromboses 
may also be treated with CDT, although the subsequent mor-
tality remains high.106 A number of randomized controlled 
trials are currently underway comparing the longer-term 
outcomes of CDT compared with anticoagulation alone.
Vena cava filters
Vena cava filters are indicated in very few circumstances. They 
include absolute contraindication to anticoagulation, life-threat-
ening hemorrhage on anticoagulation, and failure of adequate 
anticoagulation.108 Absolute contraindications to anticoagula-
tion include central nervous system (CNS) hemorrhage, overt 
gastrointestinal bleeding, retroperitoneal hemorrhage, massive 
hemoptysis, cerebral metastases, massive cerebrovascular acci-
dent, CNS trauma, and significant thrombocytopenia (,50,000/
µL).108 They may be retrievable or nonretrievable, most of the 
newly developed ones being retrievable.
Studies to assess the effectiveness of filters revealed 
significantly fewer patients suffering PE in the short term, 
but no significant effect on PE. There was a higher rate of 
recurrent DVT in the long term.109 Complications of inferior 
vena cava filters include hematoma over the insertion site, 
DVT at the site of insertion, filter migration, filter erosion 
through the inferior vena cava wall, filter embolization, and 
inferior vena cava thrombosis/obstruction.110
Conclusion
DVT is a potentially dangerous clinical condition that can lead 
to preventable morbidity and mortality. A diagnostic pathway 
involving pretest probability, D-dimer assay, and venous Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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ultrasound serves as a more reliable way of d  iagnosing DVT. 
Prevention consists of both mechanical and pharmacological 
modalities and is encouraged in both inpatients and outpatients 
who are at risk of this condition. The goal of therapy for DVT 
is to prevent the extension of thrombus, acute PE, recurrence 
of thrombosis, and the development of late complication such 
as pulmonary hypertension and post-thrombotic syndrome.
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